The vast majority (86% or 453,000 cases) of the global burden of cervical cancer occurs in Africa, Latin America and the Caribbean and Asia, where one in nine new cancer cases are of the cervix. Although the disease has become rare in high-resource settings (e.g., in North America, parts of Europe, Japan) that have historically invested in effective screening programs, the patterns and trends are variable elsewhere. While favourable incidence trends have been recorded in many populations in Asia and Latin America and the Caribbean in the past decades, rising rates have been observed in sub-Saharan African countries, where high quality incidence series are available. The challenge for countries heavily affected by the disease in these regions is to ensure resource-dependent programmes of screening and vaccination are implemented to transform the situation, so that accelerated declines in cervical cancer are not the preserve of high-income countries, but become the norm in all populations worldwide.
Introduction
In the past decades, there has been extensive research on the association between human papillomavirus (HPV) infection and cervical cancer. Researchers have reached a critical understanding of the role of HPV as a carcinogen 1 and, currently, persistent infection with high risk types of HPV is considered a necessary, although not sufficient, cause of cervical cancer. 2 Among the beneficial consequence has been the development of prophylactic HPV vaccines 3, 4 and the integration of HPV-based screening in prevention programmes to increase sensitivity for detection of precancerous cervical lesions. 5, 6 At the epidemiological level, national estimates of incidence of cervical cancer exhibits an inverse correlation with average levels of national development as represented by the Human Development index (HDI). 7 An approximately threefold difference in age-standardised cervical cancer incidence rates are observed between low and very high HDI countries, whereas the corresponding mortality rates vary six-fold. 8 This inequity is widening and reflects more the levels of resources and effective screening implementation rather than the background prevalence of high-risk HPV genotypes. The historic investment in effective screening has been large among countries with a currently high-income level but contrasts with the continued absence of such activities in many countries that are now undergoing major social and economic transition, in Africa, Latin America and the Caribbean, Asia. In unscreened populations, the disease has a relatively early age at onset, with a rapid increase in risk until approximately the age of menopause before reaching a plateau or a decline. This pattern differs to that observed in many high-resource areas, where effective screening programmes have been put in place and where the disease has become relatively rare: in these countries, the age-specific incidence curve exhibits an increase in the rates up until the age of 30-35 years and, thereafter, remains stable throughout older ages.
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Information on the changing scale and profile of cervical cancer in these regions is essential in the developing prioritised preventive actions at the national level. 12 In this article, we provide a brief summary of the diversity in rates and recent trends between and within these regions, emphasising the need for action to reduce this eminently preventable disease.
Material and Methods
National incidence and mortality rates are estimated for the major types of cancers in 184 countries by sex and age in the GLOBOCAN 2012 database, compiled by the International Agency for Research on Cancer (IARC). The methods used to estimate incidence and mortality vary depending on the availability and quality of the data sources at the national level. We analysed age-standardised cervical cancer incidence and mortality rates (age-standardized rate, world standard) and for comparison purposes, rates of other common cancers. The lifetime cumulative risk of cervical cancer for women aged 0-74 years is also presented, assuming an absence of competing causes of death. To analyse trends of cervical cancer incidence, we used data from high-quality population-based cancer registries included in the IARC publication, "Cancer Incidence in Five Continents" (CI5). 13 
Results
Cervical cancer is the fourth most common cancer in women worldwide, after breast, lung and colorectal cancer with an estimated 528,000 new cases diagnosed in 2012. Of these, 453,000 or 86% occurred either in Africa, Latin America and the Caribbean and Asia. In these regions combined, cervical cancer is the second most commonly diagnosed cancer among women, after breast cancer. It is the most commonly diagnosed cancer in women in 28 countries in Africa, seven in Latin America and the Caribbean and three countries in Asia (Fig. 1) . Mortality rates are typically about half those observed for incidence. Among a total of 266,000 cervical cancer deaths worldwide, 90% (233,000) occurred in these regions.
Africa
Overall, cervical cancer ranks as the second most common cancer and is responsible for over one-fifth of all female cancers in the continent according to GLOBOCAN estimates for 2012. The highest rates are in Eastern Africa, with the cumulative risk in Malawi, Zimbabwe and Mozambique in excess of 6%. Conversely, cervical cancer is rather uncommon in the predominantly Muslim populations in Northern Africa, where the disease comprises only 5% of the cancer burden in women. Egypt, Sudan and Tunisia all have cumulative risks below 1% (Fig. 2a) .
Latin America and the Caribbean
Cervical cancer ranks among the first five most common cancers, in terms of both incidence and mortality. In this region, the disease is estimated to be the second most common cancer after breast cancer, with 69,000 new cases and 29,000 deaths. In Latin America and the Caribbean, cervical cancer accounted for about 12% of all newly diagnosed cancers in 2012 in the region, an estimate similar to the average for low HDI countries, even though most of the countries in this region are ranked as middle or high HDI. The lifetime risk of cervical cancer incidence is highest in Bolivia, 4.9% and Nicaragua, 3.5%, the two countries with the highest mortality rates in the region, although there are marked variations in risk across populations (Fig. 2b) .
Asia
The disease remains the third most commonly diagnosed cancer (after breast and lung) with an estimated 285,000 new cases (9% of all cancer cases) and 144,000 deaths in 2012. There are, however, marked differences in incidence and mortality rates across Asian populations, reflecting the large heterogeneity in risk in the region. The incidence rates differ substantively between China and India, by far the most populated countries in Asia: rates in China (7.5 per 100,000) are three times lower than in India, where the lifetime risk of cervical cancer (ages 0-74) is 2.4%. There is however considerable regional variability in rates within these two countries. Elevated incidence is also observed in Kazakhstan, Cambodia, Mongolia, Kyrgyzstan, Myanmar and Bangladesh, where the lifetime risks are estimated to be 2% or greater (Fig. 2c) .
Cervical cancer trends
Major declines in incidence rates have been observed in many populations in Asia and Latin America and the Caribbean in the past decades, although the magnitude and the trends of cervical cancer are very variable across different countries. Increases in cervical cancer incidence have been observed in the part decades on examining the populationbased registry data in certain countries in Eastern Africa, such as Uganda and Zimbabwe (Fig. 3) .
Discussion
The large majority of cervical cancers diagnosed worldwide occur in one of the three regions, Africa, Latin America and the Caribbean or Asia. Given the relatively high costs and the requirement of an adequate health care infrastructure, mass screening programmes have not been implemented in many countries in these areas and, consequently, incidence and mortality rates often remain high relative to other regions and in absolute terms. Large geographic variations in cervical cancer incidence and mortality however exist within each of What's new? While cervical cancer burden has declined in regions with effectively implemented screening programs, the disease remains a major cause for concern in low-resource settings. This study draws attention to Africa, Latin America and the Caribbean and Asia, where mortality rates for cervical cancer were estimated to be about half the rates observed for incidence, based on analyses of GLOBOCAN 2012 data. About 90% of cervical cancer deaths globally were found to occur in these regions. The findings highlight the importance of cervical cancer screening in low-resource settings, where inequities in detection and prevention are heavily impacting women's health. these regions. Although high quality cancer registries and reliable mortality data are still relatively rare in Africa, it is clear that cervical cancer is one of the most important causes of cancer morbidity and mortality in the continent; incidence and mortality rates in sub-Saharan Africa are among the highest in the world. 14 The background prevalence of HPV infection in sub-Saharan Africa is very high, estimated to be 24% on average (ranging from 3.2% in Sudan to 47.9% in Guinea, 15, 16 and early detection programmes including cytological screening are largely absent. The study of the burden and of the long-term trends in cervical cancer incidence is possible in many parts of the (predominantly developed) world based on the data from population-based cancer registries contributing high quality data to the "Cancer Incidence in Five Continents" series (http://ci5.iarc.fr). Trends of cervical cancer are on the rise in countries where relatively long time span cancer data are available in Africa, e.g., in Kampala, Uganda, 17 or the black population of Harare, Zimbabwe. 18 The role of HIV, which was relatively high in the 1990 sec in Uganda and Zimbabwe, on the rising trends of cervical cancer incidence is, however, not clear. 15 Conversely, the incidence of cervical cancer is relatively low in the mainly Muslim countries of Northern Africa, despite the lack of mass screening programs. 19 These populations are considered 
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to have a more conservative sexual behaviour compared to other populations in sub-Saharan Africa or in western countries, and therefore the prevalence of HPV is low. 19 However, possible changes in lifestyle and sexual activities may exist among younger generations, and these cohort-specific trends should be monitored to assess the burden in the future. 19 In Latin America and the Caribbean and in Asia, there are a number of low-to-high HDI populations where cervical cancer incidence rates are relatively high. Favourable trends have been however observed in the past decades in many countries. 9 Cervical cancer prevention activities have been lacking or inefficient and, consequently, the declining trends in cervical cancer incidence are maybe due to reasons other than implementation of cervical cancer screening programs (or improved coverage). This observation could relate to declines in fertility rates and lower parity, which are known co-factors for cervical cancer, as well as to improved hygiene conditions, education and socioeconomic status, etc.
Lastly, a clear caveat in interpreting national estimates using GLOBOCAN is the required dependency on the availability and quality of the local information sources in a given country. An alphanumeric scoring system has been introduced for the 2012 estimates to describe this information (http://gco.iarc.fr/today/data-sources-methods). Data from population-based cancer registries (PBCR) regularly published in the CI5 series sets a standard for high quality national estimation, although cancer registries are available in many countries in the studied regions which produce reasonably accurate incidence rates at the population level, or at least tabulations from hospital or pathology-based series. Given an absence of local data, incidence estimates in about 30 countries in Africa, Latin America, the Caribbean and Asia had to be derived from neighbouring countries and the estimates are clearly not as robust as those in countries where national or subnational data from PBCR exist. In addition, where the registry data are subnational rather than national, we assume that the one or more registries utilised in the estimation are sufficiently representative of the national cancer profile.
Conclusions
HPV vaccination programmes can potentially reduce dramatically the future burden of cervical cancer, as well as of other HPV-related cancers. However, their impact on the incidence rates is not likely to be detectable within the next 2-3 decades. Therefore, high-quality screening programmes are still very important to prevent cervical cancer and to play a major role in bridging the gap until the longer-term effects of HPV vaccination are visible. 11 The usage of Papanicolaou (Pap) smears and the reading of cytology have been shown to reduce effectively the burden of cervical cancer. 9, 10 However, the logistical barriers and the low sensitivity requiring repeated testing, makes it an expensive option which has been rarely implemented in LMICs. In recent years, clear evidence supports the use of HPV-based tests for the detection of precursor lesions of the cervix. 20 The integration of HPV vaccine programs with HPV-based testing in screening programmes is an attractive approach which has the potential to reduce the burden of cervical cancer particularly in regions of the world heavily affected by the disease, including Africa, Latin America and the Caribbean and Asia. 21 
